PMID- 11055889
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20191104
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 37
IP  - 3 Suppl 5
DP  - 2000 Jul
TI  - New therapeutic options in deep vein thrombosis prophylaxis.
PG  - 7-9
AB  - Joint replacement surgery is complicated by a high rate of postoperative venous 
      thromboembolism (VTE). Current thromboprophylactic approaches reduce the rate of 
      VTE, but the incidence remains as high as 20% to 50%. Recombinant hirudins, such 
      as desirudin and lepirudin, function by directly inhibiting thrombin, and are a 
      new development in antithrombotic therapy. In two multicenter studies, desirudin 
      was found to be superior to unfractionated heparin (UFH) in the prevention of 
      deep vein thrombosis (DVT) after total hip alloplasty. A further trial of more 
      than 2,000 patients undergoing elective hip replacement compared the 
      thromboprophylactic efficacy of desirudin versus the low-molecular-weight heparin 
      (LMWH) enoxaparin. Desirudin was more effective than LMWH in providing effective 
      prophylaxis, and maintained superiority in patients with additional risk. 
      Desirudin was shown to be equally safe and did not require laboratory monitoring. 
      Desirudin (15 mg twice daily) is an efficient therapy for DVT prevention in hip 
      alloplasty patients at additional risk.
FAU - Eriksson, B I
AU  - Eriksson BI
AD  - Department of Orthopedic Surgery, Sahlgrenska University Hospital, Goteborg 
      University, Sweden.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Hirudins)
RN  - 0 (Recombinant Proteins)
RN  - U0JZ726775 (desirudin)
SB  - IM
MH  - Arthroplasty, Replacement, Hip
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Hirudin Therapy
MH  - Hirudins/*analogs & derivatives
MH  - Humans
MH  - Recombinant Proteins/therapeutic use
MH  - Venous Thrombosis/*prevention & control
RF  - 8
EDAT- 2000/10/31 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/10/31 11:00
PHST- 2000/10/31 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/10/31 11:00 [entrez]
AID - S0037-1963(00)90093-3 [pii]
AID - 10.1016/s0037-1963(00)90093-3 [doi]
PST - ppublish
SO  - Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. doi: 10.1016/s0037-1963(00)90093-3.